( May 15, 2025, 11:55 AM EDT) -- SAN FRANCISCO — An amended complaint filed by seven individuals who allege that Oxbryta (voxelotor), a prescription medication used for the treatment of sickle cell disease (SCD), was ineffective should be dismissed because the claims are either preempted for fail as a matter of law, Global Blood Therapeutics Inc. (GBT) and Pfizer Inc. tell a California federal court....